Skip to content
Triangle logo TriangleGet started
← Full study record

NCT07217119 · OUTCOME

DE Phase: Feladilimab Concentration When Administered in Combination With Belantamab Mafodotin

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
ng/mL
Interval / dispersion
Standard Deviation
Time frame
Predose, EOI, 2 and 24 hours postdose on C1 D1, anytime sample at C1 D4, D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at EoT (up to approximately 281 weeks)

What was measured

Blood samples were collected for PK analysis of Feladilimab when administered intravenously in combination with belantamab mafodotin.

Analysis population: PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The "0" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.

Groups in this outcome

1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab

Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).

2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab

Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.

2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab

Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6

Reported measurements

C1 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.00.00Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.00.00Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0.00.00Not reportedNot reportedNot reported
C1 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab7
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1705.3684.19Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1938.3687.81Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab5797.53013.48Not reportedNot reportedNot reported
C1 D1, 24 HOURS

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1516.9604.62Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1682.0513.07Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab5758.02782.99Not reportedNot reportedNot reported
C1 D1, 2-4 HOURS

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab5
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1914.4849.74Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2018.5671.16Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab5850.61393.26Not reportedNot reportedNot reported
C1 D4, ANYTIME SAMPLE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1091.1502.26Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1236.8432.22Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab4739.21544.46Not reportedNot reportedNot reported
C1 D8, ANYTIME SAMPLE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab876.6438.91Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab981.4374.22Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3694.71623.62Not reportedNot reportedNot reported
C2 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab499.8303.58Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab471.3187.95Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2378.01084.60Not reportedNot reportedNot reported
C2 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2407.11005.90Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2365.11099.94Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab7489.03799.51Not reportedNot reportedNot reported
C4 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab4
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1046.7245.62Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab827.0281.32Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2799.71630.91Not reportedNot reportedNot reported
C4 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab4
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1784.01373.86Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2777.51130.40Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab4573.04594.49Not reportedNot reportedNot reported
C6 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1125.5324.56Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab798.0557.71Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2995.01194.20Not reportedNot reportedNot reported
C6 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2148.51075.51Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2985.7794.72Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab7097.72374.84Not reportedNot reportedNot reported
C9 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab750.01060.66Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab643.7188.34Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2963.01158.24Not reportedNot reportedNot reported
C9 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1405.0NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2298.3559.96Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab7779.02736.50Not reportedNot reportedNot reported
C12 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab791.0907.93Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab357.0504.87Not reportedNot reportedNot reported
C12 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab1
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1901.02479.12Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1982.0192.33Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab7859.0NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
C18 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab877.0NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab774.0NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
EoT (up to ~ 281 weeks)

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab5
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab5
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab714.6435.71Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab540.2139.23Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab5330.06407.23Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.00
        value
        0.0
      2. group Id
        OG001
        spread
        0.00
        value
        0.0
      3. group Id
        OG002
        spread
        0.00
        value
        0.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, PRE-DOSE
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        684.19
        value
        1705.3
      2. group Id
        OG001
        spread
        687.81
        value
        1938.3
      3. group Id
        OG002
        spread
        3013.48
        value
        5797.5
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, END OF INFUSION
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        604.62
        value
        1516.9
      2. group Id
        OG001
        spread
        513.07
        value
        1682.0
      3. group Id
        OG002
        spread
        2782.99
        value
        5758.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, 24 HOURS
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        849.74
        value
        1914.4
      2. group Id
        OG001
        spread
        671.16
        value
        2018.5
      3. group Id
        OG002
        spread
        1393.26
        value
        5850.6
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        5
      units
      Participants
    title
    C1 D1, 2-4 HOURS
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        502.26
        value
        1091.1
      2. group Id
        OG001
        spread
        432.22
        value
        1236.8
      3. group Id
        OG002
        spread
        1544.46
        value
        4739.2
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D4, ANYTIME SAMPLE
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        438.91
        value
        876.6
      2. group Id
        OG001
        spread
        374.22
        value
        981.4
      3. group Id
        OG002
        spread
        1623.62
        value
        3694.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D8, ANYTIME SAMPLE
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        303.58
        value
        499.8
      2. group Id
        OG001
        spread
        187.95
        value
        471.3
      3. group Id
        OG002
        spread
        1084.60
        value
        2378.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        9
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C2 D1, PRE-DOSE
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        1005.90
        value
        2407.1
      2. group Id
        OG001
        spread
        1099.94
        value
        2365.1
      3. group Id
        OG002
        spread
        3799.51
        value
        7489.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        8
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C2 D1, END OF INFUSION
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        245.62
        value
        1046.7
      2. group Id
        OG001
        spread
        281.32
        value
        827.0
      3. group Id
        OG002
        spread
        1630.91
        value
        2799.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        4
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C4 D1, PRE-DOSE
  10. categories
    1. measurements
      1. group Id
        OG000
        spread
        1373.86
        value
        1784.0
      2. group Id
        OG001
        spread
        1130.40
        value
        2777.5
      3. group Id
        OG002
        spread
        4594.49
        value
        4573.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        4
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C4 D1, END OF INFUSION
  11. categories
    1. measurements
      1. group Id
        OG000
        spread
        324.56
        value
        1125.5
      2. group Id
        OG001
        spread
        557.71
        value
        798.0
      3. group Id
        OG002
        spread
        1194.20
        value
        2995.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C6 D1, PRE-DOSE
  12. categories
    1. measurements
      1. group Id
        OG000
        spread
        1075.51
        value
        2148.5
      2. group Id
        OG001
        spread
        794.72
        value
        2985.7
      3. group Id
        OG002
        spread
        2374.84
        value
        7097.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C6 D1, END OF INFUSION
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      10
    3. group Id
      OG002
      value
      6
    units
    Participants
description
Blood samples were collected for PK analysis of Feladilimab when administered intravenously in combination with belantamab mafodotin.
dispersion Type
Standard Deviation
groups
  1. description
    Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).
    id
    OG000
    title
    1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
  2. description
    Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
    id
    OG001
    title
    2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
  3. description
    Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
    id
    OG002
    title
    2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab
param Type
MEAN
population Description
PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The "0" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.
reporting Status
POSTED
time Frame
Predose, EOI, 2 and 24 hours postdose on C1 D1, anytime sample at C1 D4, D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at EoT (up to approximately 281 weeks)
title
DE Phase: Feladilimab Concentration When Administered in Combination With Belantamab Mafodotin
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice